Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CV Therapeutics, Inc.
Net loss of $0.75 per share reported by drug development company
May 14th, 2003
CV Therapeutics, Inc., (CVTX) announced financial results for the first quarter ended March 31, 2003. For the quarter ended March 31, 2003, the company reported a net loss of $20.7 million, or $0.75 per share, compared to a net loss of $21.9 million, or $0.86 per share, for the same quarter in 2002. Operating expenses for the quarter ended March 31, 2003, decreased to approximately $23.3 million, from $25.0 million for the same quarter in 2002, primarily due to decreased clinical trial expenses (consistent with the fluctuation in clinical trial activity of our late stage programs) and decreased general and administrative outside service expenses....
Source: Biotech Week (2003-05-14)
|
